Inogatran is a synthetic thrombin inhibitor, developed for the possible treatment and prophylaxis of venous and arterial thrombotic diseases.

Inogatran also improves vena caval blood flow and reduces the overall incidence of thrombotic occlusion in a rat model.Inogatran (H-314-27; 0.075, 0.25, 0.75 mg/kg, i.v.) results in dose-dependent increases in activated partial thromboplastin time (aPTT), thrombin time (TT), and prothrombin time (PT) in a canine electrolytic injury model of venous thrombosis. Inogatran dose-dependently inhibits thrombus formation, which is measured as an increase in time to occlusion (TTO) and a decrease in thrombus weight.